LEADING THE FUTURE OF CELL THERAPY
WITH OUR AlloCAR T™ PLATFORM

INNOVATION

  • Multiplex gene-engineering and gene-editing capabilities
  • Proprietary lymphodepletion platform
  • State-of-the-art manufacturing
  • Opportunity for product optimization

PIPELINE

  • Upcoming milestones
    • - Initial Phase 1 ALLO-715 UNIVERSAL trial data
    • - File IND for ALLO-316 (anti-CD70 CAR)

LEADERSHIP

  • A highly experienced management team that includes key pioneers of CAR T cell therapy
  • 200+ employees singularly focused on the development of AlloCAR T™ therapy
  • Allogene is proud to have approximately 50% of our senior leadership team and entire organization identify as female.

WE DON’T JUST SEE THE FUTURE.

WE KNOW HOW TO GET THERE.

Allogene is working to overcome the limitations of autologous CAR T immunotherapy by developing AlloCAR T™ therapies. The goal of our allogeneic platform is simple: combine gene-editing technology with cutting-edge cell-therapy manufacturing to deliver the clinical benefits of cell therapy. We start with T cells from healthy donors to allow for the creation of off-the-shelf inventory for the potential to treat all eligible patients faster, more reliably, and at greater scale.

WHY ALLOGENEIC CELL THERAPY HAS THE
POTENTIAL TO LEAD THE REVOLUTION

ACCESS

  • Potential to treat all
    eligible patients
  • Repeat dosing, if needed
  • No need for complex logistics

COST

  • Scalable and efficient manufacturing
  • Potential to treat 100+ patients from a single manufacturing run
  • Lower ancillary costs of care

SPEED/RELIABILITY

  • Off-the-shelf for on-demand treatment
  • Less product variability, made from healthy T cells

OUR PARTNERS

Cellectis
Notch Therapeutics
Servier
Spring Works Therapeutics

LATEST NEWS

©2020 ALLOGENE THERAPEUTICS